16 June – Targeted treatments for haematological cancers

Monday 16 June, Royal Marsden Hospital

1-day course: Targeted Treatments for Haematological Cancers

Level: Advanced/expert (Designed for doctors and senior oncology staff working in haematological cancers. Requires some knowledge of immunology.)

Description: This course describes and explains the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments in development for leukaemia, lymphoma and multiple myeloma. New approaches such as epigenetic modifiers and inhibitors of Bcl-2 and B cell receptor signalling are introduced and the possibility of personalised treatment is discussed.

To book, contact: henry.coleman@rmh.nhs.uk Tel. 020 7808 2922


Key molecular concepts in leukaemia, lymphoma and myeloma
  • Unique properties of myeloid and lymphoid cells
  • Common chromosome translocations and their consequences
  • Key genetic mutations & molecular pathways
Targets & treatments for blood cancers part 1
  • Monoclonal antibody technology
  • Targeting cell surface (CD) antigens with monoclonal antibody treatments and their derivatives  (eg. conjugated antibodies and bi-specific antibodies)
Targets & treatments for blood cancers part 2
  • Targeting over-active signalling pathways, including inhibitors of mTOR, NFκB, FLT3, KIT, JAK/STAT, PKC, B Cell Receptor/SYK

Practical exercise

Targets & treatments for blood cancers part 3
  • Targeting the cell cycle (Aurora Kinase & Polo-like Kinase inhibitors, CDK inhibitors, PARP inhibitors)
  • Targeting cell survival (proteasome inhibitors and Bcl-2 inhibitors)
  • Targeting epigenetics (HDAC inhibitors)
Targets & treatments for blood cancers part 4, specific treatments
  • Leukaemia: PML/RARα and BCR-ABL inhibitors
  • Lymphoma: ALK inhibitors
  • Myeloma: thalidomide + derivatives; targeting the tumour microenvironment;
    logical treatment combinations